Oncotype Breast Cancer Test Predicts Late Recurrence Five to 15 Years Out
GHDX today announced results of a large, positive study that confirmed that the Oncotype DXÂ® test results for Recurrence ScoreÂ® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in early-stage breast cancer patients after initial tamoxifen therapy, suggesting that Oncotype DX may help identify which patients have greater potential to benefit from extended hormonal treatment beyond five years. Â One of the nine Oncotype DX studies being presented at the 2014 American Society of Clinical Oncology Annual Meeting taking place in Chicago, these data will be presented on June 2 at 8:00 a.m. Central Time.
"As recognized by ASCO's guideline update, recent studies have shown that extending tamoxifen treatment for 10 years is associatedÂ with better outcomes, however, we still need better tools to identify who those patients are," said Norman Wolmark, M.D., chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP).Â "This study confirms that Oncotype DX can helpÂ better define who is at greatest risk for late recurrences and the potential to benefit from extended tamoxifen, as well as those who are at lower risk and will likely have less absolute benefit from extended tamoxifen and, thus, could be spared prolonged exposure and risk of long-term side effects."
This new study analyzed 668 and 1065 patients from the original NSABP B-14 and B-28 trials, respectively. Median follow-up of 13.9 years (B-14) and 11.2 years (B-28) determined that the Oncotype DX Recurrence Score results were significantly associated with distant recurrence after five years in patients whose tumors had high estrogen receptor expression.Â Specifically, in the NSABP B-14 patients, the association of the continuous Recurrence Score with distant recurrence after five years in the higher
Since GHDX did the stock buyback the only thing the Baker bros want is more shares. (46% of the shares) until they get to 49.9999 % of the company. Felix and co dont care what the price is ( they were buying last year at $36) - they only care the price the company gets sold for. Good Luck